Introduction: Ibogaine is being studied for opioid use disorder (OUD), but a single episode adds long-term value only if early responses last. We compared a medically monitored ibogaine episode with protocolized medication for OUD (MOUD) rescue against starting buprenorphine or methadone.,Methods: We built a weekly cohort state-transition model of treatment-presenting, eligible U.S. adults over 10 years (health care sector perspective, 2024 US$, 3% discounting). The model tracks response, first return to use, MOUD status, opioid use and mortality. Without participant-level relapse data, durability was partially identified from one cohort's grouped follow-up under three curves, none a base case. Acquisition price was excluded; threshold prices are reported. One-way, structural and probabilistic sensitivity analyses were run, the latter sampling source uncertainty only, conditional on each curve and retention schedule.,Results: Versus buprenorphine, incremental QALYs per person were 0.0024, 0.0152 and 0.0125 under the fast-bound, Tier-1 upper-edge and proportional-transport curves, at $3,937 to $6,290 more before acquisition. ICERs were $2,673,000, $259,562 and $353,661 per QALY ($2,528,000, $217,217 and $307,945 versus methadone). Under a conservative mortality mapping the strategy caused 0.28 to 0.39 more deaths per 1,000; with background mortality after response it caused fewer, and Tier-1 ICERs were $86,535 and $75,705 per QALY. No non-negative acquisition price met $150,000 per QALY. Cost-effectiveness at $100,000 per QALY required a post-month-12 return half-life of at least 89 to 195 weeks (reference 44.4). Crediting one participant with unresolved treatment-course history gave $22,684 per QALY versus buprenorphine. In conditional probabilistic analyses, none of the 1,000 parameter-uncertainty draws was cost-effective at $100,000 per QALY in any principal or retention-conditioned analysis.,Conclusions: Under the principal evidence and a conservative mortality mapping, medically monitored ibogaine with protocolized MOUD rescue was not cost-effective at willingness-to-pay thresholds up to $150,000 per QALY versus starting buprenorphine or methadone, even before including an ibogaine acquisition price. The decision could change with durability beyond one year, the classification of one participant with unresolved treatment-course history, the day-28 response definition (the available-case reading), mortality after response, and the monitoring setting and state acute-care cost gradients. Linked participant-level data are the priority.